Esta tradução está a ser preparada. Entretanto, mostramos temporariamente a versão original em inglês.
Regulação e direito · 28/12/20201 min de leitura
Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors
Tradução automática local · Idioma original da fonte
Resumo
The National Cancer Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an Exclusive Patent License to practice the inventions embodied in the Patents and Patent Applications listed in the Supplementary Information section of this Notice to Senti Bio ("Senti"), located in South San Francisco, CA.
Idioma original da fonte: Federal Register — All DocumentsAbrir o comunicado original →